U.S. markets closed
  • S&P Futures

    4,141.75
    -5.00 (-0.12%)
     
  • Dow Futures

    32,738.00
    -19.00 (-0.06%)
     
  • Nasdaq Futures

    13,221.00
    -7.75 (-0.06%)
     
  • Russell 2000 Futures

    1,919.90
    -1.90 (-0.10%)
     
  • Crude Oil

    89.28
    +0.27 (+0.30%)
     
  • Gold

    1,788.90
    -2.30 (-0.13%)
     
  • Silver

    19.84
    +0.00 (+0.02%)
     
  • EUR/USD

    1.0185
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • Vix

    21.15
    -0.29 (-1.35%)
     
  • GBP/USD

    1.2076
    +0.0006 (+0.05%)
     
  • USD/JPY

    135.0810
    +0.1110 (+0.08%)
     
  • BTC-USD

    23,308.65
    +309.53 (+1.35%)
     
  • CMC Crypto 200

    542.84
    +7.61 (+1.42%)
     
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • Nikkei 225

    28,268.00
    +92.13 (+0.33%)
     

Gilead quarterly profit falls as COVID antiviral sales decrease

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Aug 2 (Reuters) - Gilead Sciences Inc on Tuesday said its second-quarter adjusted profit fell 13% due to higher research and royalty costs as well as a downturn in sales of its COVID-19 antiviral drug Veklury.

Revenue for the quarter rose 1% to $6.3 billion, which was ahead of the average Wall Street estimate of $5.85 billion, according to Refinitiv data.

The biotech company said adjusted quarterly profit fell 13% to $1.58 per share, which also topped the average analyst estimate of $1.52. Quarterly net income fell to 91 cents per share from $1.21 per share.

Sales of COVID-19 treatment remdesivir, which is sold under the brand name Veklury, fell 46% to $445 million, exceeding analysts' estimates of $390 million.

The cancer drug Trodelvy - shown in a recent trial to modestly delay tumor growth in women with the most common form of breast cancer - saw sales rise 79% to $159 million.

Gilead said its HIV drug sales, driven by demand for higher-priced products, rose 7% to $4.2 billion.

For full-year 2022, the California-based company sightly raised its forecast for adjusted earnings per share to between $6.35 to $6.75 from a previous view of $6.20 to $6.70. Gilead said it now expects product sales of $24.5 billion to $25 billion, up from a previous estimate of $23.8 billion to $24.3 billion.

(Reporting By Deena Beasley Editing by Bill Berkrot)